65273-64-5

Usage

Uses

Used in Pharmaceutical Industry:
[2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl](triphenyl)phosphonium is used as a potential pharmaceutical compound for its organophosphorus nature, which may offer various therapeutic applications. The specific properties and uses within the pharmaceutical sector require further research and development to fully understand its potential.
Used in Chemical Synthesis:
In the field of chemical synthesis, [2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl](triphenyl)phosphonium can be used as a reagent or intermediate due to its unique molecular structure. Its organophosphorus composition may facilitate the creation of new compounds with specific properties, contributing to the advancement of chemical research.
Used in Flame Retardants:
Given its organophosphorus nature, [2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl](triphenyl)phosphonium may also be utilized as a component in the development of flame retardants. Further investigation is necessary to determine its effectiveness and safety in this application.
Used in Pesticides:
As organophosphorus compounds are known for their use in the agricultural industry, particularly as pesticides, [2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)ethyl](triphenyl)phosphonium could potentially be employed in the development of new pesticides. Its specific role and effectiveness in this industry would need to be explored through additional research.

Upstream product

• 574-98-1 2-(2-bromoethyl)isoindoline-1,3-dione 
• 603-35-0 triphenylphosphine 

Downstream Products

• 374813-31-7 2-[3-(4-chlorophenyl)propyl]-1H-isoindole-1,3(2H)-dione 
• 195053-88-4 2-[3-(1-trityl-1H-imidazol-4-yl)propyl]isoindoline-1,3-dione 
• 112547-04-3 (E)-N-[3-(1-Triphenylmethyl-1H-imidazol-4-yl)allyl]phthalimid 
• 111157-54-1 (Z)-N-<3-(1-Triphenylmethyl-1H-imidazol-4-yl)allyl>phthalimid 

Relevant academic research and scientific papers

Synthesis and evaluation of N-alkyl-S-[3-(piperidin-1-yl)propyl] isothioureas: High affinity and human/rat species-selective histamine H 3 receptor antagonists

S-Alkyl-N-alkylisothiourea compounds containing various cyclic amines were synthesized in the search for novel nonimidazole histamine H3 receptor (H3R) antagonists. Among them, four N-alkyl S-[3-(piperidin-1-yl)propyl]isothioureas 18, 19, 22, and 23 were found to exhibit potent and selective H3R antagonistic activities against in vitro human H3R, but were inactive against in vitro human H 4R. Furthermore, three alkyl homologs 18-20 showed inactivity for histamine release in in vivo rat brain microdialysis, suggesting differences in antagonist affinities between species. In addition, in silico docking studies of N-[4-(4-chlorophenyl)butyl]-S-[3-piperidin-1-yl)propyl]isothiourea 19 and a shorter homolog 17 with human/rat H3Rs revealed that structural differences between the antagonist-docking cavities of rat and human H 3Rs were likely caused by the Ala122/Val122 mutation.

Novel H3 receptor antagonists. Sulfonamide homologs of histamine.

Sulfonamides derived from 4(5)-(omega-aminoalkyl)-1H-imidazoles containing chain lengths of three- to five-carbons were synthesized. Good to moderate H3 receptor binding affinities were observed for several butyl and pentyl homologs, whereas binding affinities were considerably weaker in the propyl series. Separation of the imidazole ring and the sulfonamide unit by a four- or five-carbon tether afforded potent H3 receptor antagonists.

Synthesis and antitumor properties of some isoindolylalkylphosphonium salts

Antitumor evaluation of 2-(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl) ethyltriphenylphosphonium bromide (1) revealed significant activity in P-388 lymphocytic leukemia (T/C = 160%). As a follow-up to this chemical lead, a series of closely related phosphonium salts was prepared in which the 1,3-dihydro-1,3-dioxo-2H-isoindole ring system was maintained or in which it was replaced by other moieties such as maleimido, bromo, methoxy, and isoindoline. Syntheses generally involved treatment of the appropriate N-(bromoalkyl)phthalimide with the required phosphine or condensation of the K salt of the substituted imide with β-(bromoethyl) triphenylphosphonium bromide. From the biological data obtained for these compounds, several requirements can be defined for substantial antileukemic activity. Of utmost importance is the presence of a triarylphosphonium halide moiety, coupled to an alkyl chain of two or three carbon atoms. The preferred terminus of the alkyl chain is the 1,3-dihydro-1,3-dioxo-2H-isoindole ring system, although the observed activity of β-(bromoethyl)triphenylphosphonium bromide (T/C = 127%) would suggest that a superior carrier molecule could be developed.